Page 763 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 747

Diamond-black an anemia Endothelium, 490 measurement
diagnosis, 250 Eosinophilia, 337 mean corpuscular hemoglobin (MCH), 213

pathophysiology, 250 Eosinophilic granules, 98 mean corpuscular hemoglobin concentration
treatment, 250 Eosinophils (MCHC), 213–214
Diamond-black an anemia (DBA), 250 assessment methods, 249, 217 mean corpuscular volume, 212
Diapedesis, 166, 176 development, 165, 165 values, 123, 124t

DIC (see Disseminated intravascular coagulation) distribution, 165–166 membrane characteristics
Dideoxy method, 659 granulation, 168–169 aging red blood cell, 114
Dif use large B-cell lymphoma (DLBCL) maturation, 165, 165 mature red blood cell, 113–114
classi cation, 431 maturational characteristics reticulocyte, 112–113

clinical signs and symptoms, 431 metamyelocyte, 167–168, 168 metabolic activities
epidemiology, 431, 431 myeloblast, 166, 167 Embden–Meyerh o pathway, 114
laboratory characteristics, 431 myelocytes, 167, 168 Luebering–Rapoport pathway, 115
Dif usion, 59 promyelocyte, 166–167, 168 methemoglobin reductase pathway, 114–115

DiGeorge syndrome, 362 mature orms, 168 oxidative pathway, 114
Digital cell morphology, 638–639 production, 164–165 metabolic pathways, 112t
Digital microscopy Ependyma, 585 morphology, grading, 220, 220t
arti cial neural networks (ANNs), 638 Epigenetics, 64 nomenclature, 144t

Cellavision DM-1200, 638, 638 Epstein-Barr virus (EBV), 356–359, 357, 362, 376 normal and abnormal, 142
digital cell morphology, 638–639 Erythroblastic islands, 105 osmotic ragility o , 685–686, 686
Diphyllobothrium latum, 282 Erythroblastopenia, 249 quantitative assessment
Dipotassium ethylenediaminetetraacetate (K Erythroblasts, 97, 105 blood volume measurement, 211–212
2
ED A), 28 Erythrocyte sedimentation rate (ESR), 2, 218 hematocrit (Hct), 211
Direct thrombin inhibitors, 575 Erythrocytes, 97, 98 hemoglobin (Hb) measurement, 211
Disin ection abnormalities, 478 packed cell volume, 211
de nition, 9 agglutination, 152 red blood cell indices, 212–214

household bleach, 9t aging, 115 red cell count manual methods, 212
procedure, 9–10 catabolism reticulocytes, 214–216
solutions, 9 extravascular, 115, 132, 132 rule o three, 211
Disseminated intravascular coagulation (DIC), intravascular, 115, 132–133, 133 quantitative descriptors o

507, 507 color alterations, 149–150 MCV and RDW, classi cation, 629, 629t
destruction and consumption disorders complete blood cell (CBC), 119 RDW vs. MCV, 628, 628t
acute consumptive coagulopathy, 562, 562t cytoplasmic characteristics, 114 red cell distribution width, 628, 628
alternate orms o , 561 developmental stages reticulocytes

clinical and laboratory mani estations, 562, early cells, 106–107 calculation, 215
562b maturation, 111 count, 214–215
etiology, 559–560 metarubricyte, 109, 109 production index, 215
actor VIII, 561 prorubricyte, 107–108 Rh testing, 136

laboratory ndings, 562–563 reticulocyte, 109 rouleaux ormation, 152, 152
pathophysiology, 560–561 rubriblast, 107 sedimentation rate
protein C, 561–562 rubricyte, 108–109 G6PD, 681
thrombin, 562 disorders related Westergren method, 678–679

vs. thrombotic thrombocytopenia purpura, abnormal hemoglobin, 129–130 Wintrobe method, 679
562, 563t de ective nuclear maturation, 111–112 semiquantitative grading, 220
renal disease, 551 erythropoietin, 111 time correction actor, maturation, 215, 215t
DNA ploidy and cell cycling, 637, 637 genetics and iron de ciency, 262–263 variation, shape

DNA sequencing, 658–660, 659–661 globulin synthesis, 128, 272 acanthocytes, 144, 145
Döhle bodies, 340t, 341, 342 heme/porphyrin synthesis, 127, 271–272 bite cells, 145, 146
Donath–Landsteiner screening test, 681 hemoglobin analysis, 130–131 blister cells, 145–146, 146
Down syndrome (DS), 375–376 ontogeny, 128–129 burr cells, 146, 147

Dri , 18 red cell increases, 111 codocytes, 148, 148–149
Drug-induced aplastic anemia, 245 variant orms, hemoglobin, 129 degmacytes, 146
Drug-induced immune hemolytic anemia energy metabolism, 112 echinocytes, 146, 147
(DIIHA), 304 erythropoietin, 105 elliptocytes, 146, 147

Dyskeratosis congenita, 249 hemoglobin helmet cells, 146, 147
Dysmegakaryocytopoiesis, 464 2,3-diphosphoglycerate role, 120 keratocytes, 146, 147
Dysplasia, 61, 62 biosynthesis, 123–126, 270–272 knizocytes, 146
characteristics, 388t carbon dioxide transport, 122–123 leptocytes, 146

chemical composition, 120 oval macrocytes, 146, 147
E genetic inheritance, 120 poikilocytosis, 143, 143
Ecarin clotting time (EC ), 536 oxygen alterations, 122 pyknocytes, 146, 147
Ecchymosis, 505, 505 oxygen dissociation, 121, 121–122 schistocytes, 146, 147

Echinocytes, 146, 147 histogram, 627, 627 schizocytes, 146, 147
Edema, 39 inclusions sickle cells, 146, 148, 148
Ef usion, 592 basophilic stippling, 150, 151 spherocytes, 148, 148
Ehlers-Danlos syndromes (EDS), 507 cabot rings, 150, 151 spiculated erythrocytes, 148

Ehrlichia, 340t, 341–342, 342 crystals, 150, 151 stomatocytes, 148, 148
Electrical impedance principle, 619, 620, 621 heinz bodies, 150, 151 target cells, 148, 148–149
Electrophoresis, 130, 130, 131, 131 Howell–Jolly bodies, 150, 151, 152 teardrop cells, 149, 149
Elliptocytes, 146, 147 pappenheimer bodies, 152, 152 variation, size, 142–143

Embden–Meyerh o pathway, 114 parasitic, 152–157 Erythrocytic enzyme de ects, 299
Endocytosis, 60 punctate stippling, 150, 151 Erythrocytosis, 111
Endoplasmic reticulum (ER), 62 siderotic granules, 152, 152 Erythroleukemia, 388
Endoreduplication, 493 staining characteristics, 150t Erythropoiesis, 82, 91

Endothelial dys unction, 492 manual cell counting, 210, 211t developmental stages
Endothelins, 492 maturation, 123, 125 early cells, 106–107